World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Immunology 103 637 589 372 337 397 41398
Medicine 103 7321 6879 3831 3546 409 41745

Myron J. Levin publications per year

The chart shows the history of publications by Myron J. Levin between 1954 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Myron J. Levin published across 72 years, from 1954 to 2025, averaging 6 papers a year. Output peaked at 22 publications in 2018. 10 of the 432 publications appeared in the last two years.

No. of publications
5 10 15 20
Bar chart. Horizontal axis: year, 1954 to 2025. Vertical axis: number of publications, 0 to 22. Peak 22 publications in 2018. 1954: 3 publications 1955: 0 publications 1956: 0 publications 1957: 0 publications 1958: 1 publication 1959: 0 publications 1960: 0 publications 1961: 0 publications 1962: 1 publication 1963: 1 publication 1964: 0 publications 1965: 0 publications 1966: 0 publications 1967: 0 publications 1968: 0 publications 1969: 3 publications 1970: 2 publications 1971: 7 publications 1972: 1 publication 1973: 5 publications 1974: 2 publications 1975: 1 publication 1976: 1 publication 1977: 3 publications 1978: 5 publications 1979: 5 publications 1980: 3 publications 1981: 2 publications 1982: 6 publications 1983: 4 publications 1984: 9 publications 1985: 9 publications 1986: 5 publications 1987: 8 publications 1988: 5 publications 1989: 10 publications 1990: 4 publications 1991: 8 publications 1992: 5 publications 1993: 6 publications 1994: 8 publications 1995: 7 publications 1996: 7 publications 1997: 5 publications 1998: 7 publications 1999: 1 publication 2000: 2 publications 2001: 6 publications 2002: 3 publications 2003: 7 publications 2004: 6 publications 2005: 5 publications 2006: 8 publications 2007: 13 publications 2008: 12 publications 2009: 11 publications 2010: 19 publications 2011: 9 publications 2012: 15 publications 2013: 12 publications 2014: 12 publications 2015: 12 publications 2016: 16 publications 2017: 12 publications 2018: 22 publications 2019: 21 publications 2020: 5 publications 2021: 15 publications 2022: 5 publications 2023: 14 publications 2024: 7 publications 2025: 3 publications
1954 2025

432 publications in total across all disciplines

View publications per year as a table
Myron J. Levin: publications per year, 1954 to 2025
Year Publications
1954 3
1955 0
1956 0
1957 0
1958 1
1959 0
1960 0
1961 0
1962 1
1963 1
1964 0
1965 0
1966 0
1967 0
1968 0
1969 3
1970 2
1971 7
1972 1
1973 5
1974 2
1975 1
1976 1
1977 3
1978 5
1979 5
1980 3
1981 2
1982 6
1983 4
1984 9
1985 9
1986 5
1987 8
1988 5
1989 10
1990 4
1991 8
1992 5
1993 6
1994 8
1995 7
1996 7
1997 5
1998 7
1999 1
2000 2
2001 6
2002 3
2003 7
2004 6
2005 5
2006 8
2007 13
2008 12
2009 11
2010 19
2011 9
2012 15
2013 12
2014 12
2015 12
2016 16
2017 12
2018 22
2019 21
2020 5
2021 15
2022 5
2023 14
2024 7
2025 3
Total 432
Download as CSV

Myron J. Levin publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Myron J. Levin sits on this spectrum.

No. of scientists
50 100 150
Bar chart with 76 bars. Horizontal axis: publications, 62–71 to 807+. Vertical axis: number of scientists, 0 to 189. Most scientists, 189, have 152–161 publications. The last bar groups every scientist with 807 publications or more. The highlighted bar, 392–401 publications, is where this scientist sits. 62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientist 807+ publications: 100 scientists
62–71 publications 807+

This scientist: 397 publications — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

View publications distribution as a table
Number of Immunology scientists by publication count, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
Publications Scientists This scientist
62–71 9
72–81 23
82–91 40
92–101 72
102–111 86
112–121 108
122–131 150
132–141 160
142–151 159
152–161 189
162–171 166
172–181 181
182–191 188
192–201 187
202–211 178
212–221 158
222–231 168
232–241 159
242–251 160
252–261 148
262–271 116
272–281 125
282–291 115
292–301 111
302–311 95
312–321 97
322–331 97
332–341 99
342–351 96
352–361 69
362–371 76
372–381 71
382–391 71
392–401 62 397
402–411 54
412–421 41
422–431 63
432–441 53
442–451 31
452–461 42
462–471 40
472–481 29
482–491 34
492–501 30
502–511 23
512–521 41
522–531 29
532–541 28
542–551 16
552–561 18
562–571 18
572–581 17
582–591 17
592–601 17
602–611 19
612–621 13
622–631 12
632–641 11
642–651 16
652–661 9
662–671 5
672–681 13
682–691 12
692–701 6
702–711 6
712–721 9
722–731 9
732–741 6
742–751 11
752–761 10
762–771 7
772–781 12
782–791 7
792–801 5
802–806 1
807+ 100
Download as CSV

Myron J. Levin D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Myron J. Levin sits on this spectrum.

No. of scientists
50 100 150 200
Bar chart with 60 bars. Horizontal axis: D-Index, 40–41 to 157+. Vertical axis: number of scientists, 0 to 201. Most scientists, 201, have 58–59 D-Index. The last bar groups every scientist with 157 D-Index or more. The highlighted bar, 102–103 D-Index, is where this scientist sits. 40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40–41 D-Index 157+

This scientist: 103 D-Index — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

View D-Index distribution as a table
Number of Immunology scientists by D-index, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
D-Index Scientists This scientist
40–41 28
42–43 91
44–45 157
46–47 192
48–49 175
50–51 188
52–53 177
54–55 155
56–57 194
58–59 201
60–61 197
62–63 201
64–65 173
66–67 167
68–69 172
70–71 199
72–73 184
74–75 133
76–77 163
78–79 127
80–81 121
82–83 125
84–85 121
86–87 102
88–89 96
90–91 75
92–93 72
94–95 74
96–97 66
98–99 68
100–101 49
102–103 60 103
104–105 54
106–107 36
108–109 23
110–111 52
112–113 41
114–115 34
116–117 25
118–119 28
120–121 11
122–123 20
124–125 27
126–127 19
128–129 20
130–131 16
132–133 17
134–135 14
136–137 15
138–139 9
140–141 11
142–143 9
144–145 9
146–147 7
148–149 7
150–151 7
152–153 5
154–155 8
156 6
157+ 96
Download as CSV

Overview

Myron J. Levin is affiliated with the University of Colorado Anschutz Medical Campus in the United States. Their research predominantly lies within the field of Medicine, with a particular focus on Epidemiology and Infectious Diseases. Additional subfields of interest include Health, Dermatology, and Genetics.

The main topics covered in their work include:

  • Herpesvirus Infections and Treatments
  • Influenza Virus Research Studies
  • SARS-CoV-2 and COVID-19 Research
  • Vaccine Coverage and Hesitancy
  • Respiratory viral infections research
  • Cytomegalovirus and herpesvirus research
  • Dermatology and Skin Diseases

Levin has contributed to multiple recent publications, some of which are:

  • "Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials," 2020, Lara D. Veeken
  • "Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals," 2020, Journal of the American Geriatrics Society
  • "Vaccines for older adults," 2021, BMJ
  • "LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults," 2021, Open Forum Infectious Diseases
  • "AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019," 2022, Clinical Infectious Diseases

Their frequent collaborators include:

  • Adriana Weinberg
  • Michael Johnson
  • Maarten J. Postma
  • Andrew Ustianowski
  • Katie Streicher

Levin's work is often published in the following venues:

  • Open Forum Infectious Diseases
  • The Journal of Infectious Diseases
  • UNC Libraries
  • Human Vaccines & Immunotherapeutics
  • Vaccines

Best Publications

  • A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

    M. N. Oxman;M. N. Oxman;M. J. Levin;G. R. Johnson;K. E. Schmader

  • 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host

    Lorry G. Rubin;Myron J. Levin;Per Ljungman;E. Graham Davies

  • Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults

    Himal Lal;Anthony L. Cunningham;Olivier Godeaux;Roman Chlibek

  • Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

    A. L. Cunningham;H. Lal;M. Kovac;R. Chlibek

  • Recommendations for the management of herpes zoster.

    Robert H. Dworkin;Robert W. Johnson;Judith Breuer;John W. Gnann;John W. Gnann

  • Executive Summary: 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host

    Lorry G. Rubin;Myron J. Levin;Per Ljungman;Per Ljungman;E. Graham Davies

  • Guidelines for preventing opportunistic infections among HIV-infected persons - 2002

    Henry Masur;Jonathan E. Kaplan;King K. Holmes;Beverly Alston

  • Herpes Simplex Virus Resistance to Acyclovir and Penciclovir after Two Decades of Antiviral Therapy

    Teresa H. Bacon;Myron J. Levin;Jeffry J. Leary;Robert T. Sarisky

  • Efficacy Results of a Trial of a Herpes Simplex Vaccine

    Robert B. Belshe;Peter A. Leone;David I. Bernstein;Anna Wald

  • Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

    Mark H. Einstein;Mira Baron;Myron J. Levin;Archana Chatterjee

  • Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50–59 Years

    Kenneth E. Schmader;Myron J. Levin;John W. Gnann;John W. Gnann;Shelly A. McNeil

  • The rationale for quadrivalent influenza vaccines

    Christopher S. Ambrose;Myron J. Levin

  • Resistance to Antiviral Drugs of Herpes Simplex Virus Isolated from a Patient Treated with Acyclovir

    Clyde S. Crumpacker;Lowell E. Schnipper;Steven I. Marlowe;Patricia N. Kowalsky

  • Varicella-Zoster Virus–Specific Immune Responses in Elderly Recipients of a Herpes Zoster Vaccine

    M. J Levin;M. N Oxman;J. H Zhang;G. R Johnson

  • Decline in Varicella-Zoster Virus (VZV)–Specific Cell-Mediated Immunity with Increasing Age and Boosting with a High-Dose VZV Vaccine

    Myron J. Levin;Jeffrey G. Smith;Robin M. Kaufhold;Debra Barber

  • Validation of a 3-factor scoring model for the Pittsburgh sleep quality index in older adults.

    Jason C Cole;Sarosh J Motivala;Daniel J Buysse;Michael N Oxman

  • Epidemiology, clinical presentation and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women

    David I. Bernstein;Abbie R. Bellamy;Edward W. Hook;Myron J. Levin

  • Growth Inhibition by Acycloguanosine of Herpesviruses Isolated from Human Infections

    Clyde S. Crumpacker;Lowell E. Schnipper;John A. Zaia;Myron J. Levin

  • Advances in the understanding of the pathogenesis and epidemiology of herpes zoster

    Anne A. Gershon;Michael D. Gershon;Judith Breuer;Myron J. Levin

  • Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory.

    Paul M. Coplan;Paul M. Coplan;Kenneth Schmader;Alexander Nikas;Ivan S.F. Chan

  • The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study.

    Mélanie Drolet;Marc Brisson;Kenneth E. Schmader;Myron J. Levin

  • Varicella-Zoster Virus–Specific Immune Responses to Herpes Zoster in Elderly Participants in a Trial of a Clinically Effective Zoster Vaccine

    Adriana Weinberg;Jane H. Zhang;Michael N. Oxman;Gary R. Johnson

  • Airborne Transmission of Chickenpox in a Hospital

    Jeanne M. Leclair;John A. Zaia;Myron J. Levin;Richard G. Congdon

  • Prevention of Cytomegalovirus Infection by Cytomegalovirus Immune Globulin After Marrow Transplantation

    J D Meyers;J Leszczynski;J A Zaia;N Flournoy

Frequent Co-Authors

Adriana Weinberg
Adriana Weinberg University of Colorado Anschutz Medical Campus
Michael N. Oxman
Michael N. Oxman University of California, San Diego
Kenneth E. Schmader
Kenneth E. Schmader Duke University
Anthony R. Hayward
Anthony R. Hayward Brown University
Anthony L. Cunningham
Anthony L. Cunningham University of Sydney
Anne A. Gershon
Anne A. Gershon Columbia University
Shelly A. McNeil
Shelly A. McNeil Dalhousie University
Michael R. Irwin
Michael R. Irwin University of California, Los Angeles
Janet E. McElhaney
Janet E. McElhaney Health Sciences North
Clyde S. Crumpacker
Clyde S. Crumpacker Beth Israel Deaconess Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying immunology opens doors to diverse healthcare careers, many of which can be enhanced through specialized nursing programs. For example, pursuing the cheapest psych np programs can provide an affordable pathway for those interested in combining immunology with mental health care.

Understanding potential earnings is crucial when selecting a career path. The dnp salary data helps students and professionals evaluate financial prospects across various states, aiding informed decisions about where to study and work.

For nursing professionals, career advancement is always a priority. Transitioning to specialized roles is made easier through programs like the fnp to acute care np bridge program, which supports nurse practitioners moving into acute care — a field closely linked with immunology and critical care.

Additionally, enrolling in an accelerated nurse practitioner program enables motivated students to fast-track their nursing careers, gaining essential skills that complement their immunology background.

Best Scientists Citing Myron J. Levin

Trending Scientists

Recently Published Articles